<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant therapy in non-ST elevation acute coronary syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant therapy in non-ST elevation acute coronary syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anticoagulant therapy in non-ST elevation acute coronary syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Michael Lincoff, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute myocardial infarction results from rupture of an atherosclerotic plaque, which leads to intraluminal thrombosis. Intraluminal thrombus impairs distal blood flow and may lead to myocardial ischemia or infarction. Intraluminal hemostasis is a dynamic process involving both clot formation and intrinsic fibrinolysis. The goal of antithrombotic therapy (the combination of anticoagulant and antiplatelet therapy) is to prevent clot extension and reformation in cases where the clot has undergone fibrinolysis either by intrinsic mechanisms, fibrinolytic treatment, or mechanical means. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and  <a class="medical medical_review" href="/d/html/115790.html" rel="external">"Mechanisms of acute coronary syndromes related to atherosclerosis"</a>.)</p><p>This topic will review the evidence that supports the use of parenteral anticoagulant therapy in all patients with acute non-ST elevation acute coronary syndromes (NSTEACS), which include both unstable angina and acute non-ST elevation myocardial infarction. The topic will provide recommendations for its use according to whether the patient receives reperfusion with percutaneous coronary intervention or no reperfusion therapy. Information regarding anticoagulant agents in ST-elevation myocardial infarction and the role of antiplatelet therapy in NSTEACS is found elsewhere. (See  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION OF ANTICOAGULANT AGENTS</span><span class="headingEndMark"> — </span>There are three classes of anticoagulants that have been evaluated in the management of acute coronary syndromes:</p><p class="bulletIndent1"><span class="glyph">●</span>The heparins, including <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) and the low molecular weight heparins (LMWH), are indirect thrombin inhibitors that complex with antithrombin (AT, formerly known as AT III) and convert AT from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent1">There are a few limitations to UFH therapy in patients with acute myocardial infarction. One potential issue is binding to circulating plasma proteins, which renders inter- and intra-patient dosing unpredictable and requires continuous intravenous rather than subcutaneous dosing for consistent anticoagulant effect. The propensity to develop heparin-induced thrombocytopenia is another limitation. (See  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1">LMWH inactivates factor Xa, like UFH, but has a lesser effect on thrombin  (<a class="graphic graphic_figure graphicRef101832" href="/d/graphic/101832.html" rel="external">figure 1</a>). LMWH does not prolong the aPTT in a predictable fashion. They have a number of advantages over UFH, including a more predictable anticoagulant effect and a reduced likelihood of inducing immune-mediated thrombocytopenia.</p><p></p><p class="bulletIndent1">LMWHs include <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="10060" href="/d/drug information/10060.html" rel="external">nadroparin</a>, <a class="drug drug_general" data-topicid="10009" href="/d/drug information/10009.html" rel="external">tinzaparin</a>, and <a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a>. The last three have been compared with placebo, UFH, or enoxaparin [<a href="#rid1">1-5</a>]. These three seem to be as effective as UFH, may be less effective than enoxaparin, and may be associated with higher rates of major bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The synthetic heparin pentasaccharide <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> acts through antithrombin to exclusively neutralize factor Xa. Fondaparinux is the only non-heparin factor Xa inhibitor that has been evaluated for efficacy and safety in patients with NSTEACS and is available for clinical use. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct factor Xa inhibitors'</a>.)</p><p></p><p>The direct thrombin inhibitors (eg, <a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>, inogatran, efegatran, lepirudin, hirudin, and <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> [Hirulog]) bind to and inactivate one or more of the active sites on the thrombin molecule [<a href="#rid6">6</a>]. While early studies suggested benefit from many of them when compared with heparin [<a href="#rid7">7</a>], only bivalirudin is clinically used. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct thrombin inhibitors'</a>.)</p><p class="headingAnchor" id="H3397925933"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Anticoagulant therapy should be given as soon as possible after diagnosis to all patients with NSTEACS. The recommendation for use in all patients is based on early studies with <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) and <a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a> (a low molecular weight heparin), which found that anticoagulant therapy leads to better outcomes, such as a reduction in the rate of myocardial infarction, than no therapy [<a href="#rid8">8,9</a>]. The recommendation for early use is based on the fact that this therapy was started within a few hours of diagnosis in all randomized trials.</p><p>The choice between UFH, <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>, or <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> is determined by whether the patient is managed by an early invasive or a conservative approach, as well as local practice (see  <a class="medical medical_review" href="/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients managed with a conservative approach, we prefer either <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> given at the time of diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients managed with an invasive strategy (angiography, usually within 48 hours), we prefer UFH given at the time of diagnosis in most cases. This recommendation also applies to patients who will undergo angiography within four hours, referred to as the immediate angiography approach. <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> makes less sense in this setting, as heparin or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> would need to be added to fondaparinux soon after starting the latter.</p><p></p><p class="bulletIndent1">We prefer UFH to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> in patients receiving <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> for reasons of a possibly lower rate of stent thrombosis and lower cost. For patients receiving <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, either bivalirudin or UFH is reasonable as a procedural anticoagulant if percutaneous coronary intervention is performed. Although bivalirudin was used upstream of cardiac catheterization in one trial, we rarely use bivalirudin outside of the cardiac catheterization laboratory. For patients with femoral artery access and concern for higher risk of bleeding, bivalirudin is a reasonable choice.</p><p></p><p class="bulletIndent1">For patients who undergo an invasive approach, and who were started on <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, switching to heparin or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> is mandatory, as the risk of intracoronary catheter thrombosis appears to be increased with fondaparinux treatment alone. (See <a class="local">'Invasive approach'</a> below.)</p><p></p><p class="headingAnchor" id="H2175136526"><span class="h1">CONSERVATIVE APPROACH</span><span class="headingEndMark"> — </span>For patients managed with a conservative approach (revascularization not intended), we prefer either <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH). The choice between fondaparinux and enoxaparin should be determined by issues of cost and local practice. For patients at increased risk of bleeding  (<a class="graphic graphic_table graphicRef50176" href="/d/graphic/50176.html" rel="external">table 1</a>), based on the findings in OASIS-5, some of our experts prefer fondaparinux to enoxaparin. (See <a class="local">'Invasive approach'</a> below.)</p><p></p><p>In patients managed conservatively, <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> leads to fewer adverse cardiovascular events when compared with UFH. In addition, enoxaparin is easier to administer (subcutaneous as opposed to the intravenous route with UFH) and requires no laboratory monitoring. <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> has not been adequately assessed in this population.</p><p>In the following three trials, all or most of the patients were approached with a conservative strategy. These trials had differing populations and cointerventions:</p><p class="bulletIndent1"><span class="glyph">●</span>The ESSENCE trial compared the effectiveness of <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> with continuous UFH in 3171 aspirin-treated patients with unstable angina (angina at rest) or acute non-ST elevation myocardial infarction (NSTEMI); therapy was given for a minimum of 48 hours to a maximum of eight days [<a href="#rid10">10</a>]. Revascularization was not intended in this trial. At 30 days, enoxaparin therapy had a significant lower rate of a combined end point of death, MI, and recurrent angina (19.8 versus 23.3 percent with UFH) or a revascularization procedure (27.0 versus 32.2 percent). There was no difference between the two groups in the rates of major bleeding (6.5 versus 7.0 percent) or severe thrombocytopenia (0.4 versus 0.6 percent) [<a href="#rid11">11</a>]. These benefits were maintained at one year [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefits of <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> compared with UFH in NSTEACS patients were confirmed in the TIMI 11B trial of 3910 aspirin-treated patients for whom revascularization was not intended [<a href="#rid13">13</a>]. The incidence of the primary end point (death, MI, or urgent revascularization) was significantly lower with enoxaparin at eight days (12.4 versus 14.5 for heparin). The benefit of enoxaparin was limited to patients with elevated levels of troponin I [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Phase A of the A to Z trial, 3987 patients with an NSTEACS (74 percent NSTEMI) were randomly assigned to <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> or UFH [<a href="#rid15">15</a>]. An early invasive strategy was declared in 55 percent of the study subjects, at the discretion of the physician. At seven days, there was no significant difference in the incidence of the primary end point (death, MI, or refractory ischemia) between the enoxaparin and UFH arms (8.4 versus 9.4 percent, respectively; hazard ratio 0.88; 95% CI 0.71-1.08). However, in the subgroup of patients who were treated with an intended early conservative strategy, there was a significant reduction in the primary end point with enoxaparin (7.7 versus 10.6 percent). The incidence of major bleeding was greater with enoxaparin (0.9 versus 0.4 percent with UFH; p = .05), but there was no increase in transfusion rates.</p><p></p><p class="headingAnchor" id="H2617699031"><span class="h1">INVASIVE APPROACH</span><span class="headingEndMark"> — </span>For NSTEACS patients managed with an invasive approach (angiography and possible revascularization within 48 hours), we prefer <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH; given as soon as possible after diagnosis) to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>, <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, or <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>. While UFH and bivalirudin have similar efficacy and safety outcomes, there is a significant cost advantage to UFH.</p><p class="headingAnchor" id="H1854300994"><span class="h2">Unfractionated heparin compared with enoxaparin</span><span class="headingEndMark"> — </span>For most NSTEACS patients undergoing an invasive strategy, we prefer UFH to <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> based on an increased rate of bleeding with the latter. There is no evidence to support the use of other low molecular weight heparins.</p><p>The SYNERGY trial provides the best evidence with which to compare UFH with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> in patients who receive contemporary antiplatelet therapy [<a href="#rid16">16,17</a>]. This trial randomly assigned 10,027 patients with an NSTEACS to open label enoxaparin or UFH. Coronary angiography was performed in 92 percent of the SYNERGY patients; 47 percent underwent percutaneous coronary intervention (PCI), and 19 percent underwent surgical revascularization.</p><p>There was no significant difference in the rate of the primary end point of death or nonfatal myocardial infarction (MI) at 30 days or at six months with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (14.0 versus 14.5 percent and 17.6 versus 17.8 percent, enoxaparin compared with UFH). There was also no difference in death or nonfatal MI or in all-cause mortality at one year (7.4 versus 7.8 percent). However, there was a significant increase in in-hospital major bleeding with enoxaparin (9.1 versus 7.6 percent for UFH).</p><p class="headingAnchor" id="H3076151766"><span class="h2">Unfractionated heparin compared with bivalirudin</span><span class="headingEndMark"> — </span>For most NSTEACS patients undergoing an invasive strategy, we prefer UFH to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> for reasons of cost and a possibly higher rate of stent thrombosis with bivalirudin. For patients who have undergone coronary angiography, bivalirudin is a reasonable alternative to heparin plus a glycoprotein (GP) IIb/IIIa inhibitor. The most contemporary study that compared bivalirudin with UFH was the 2017 open-label VALIDATE-SWEDEHEART randomized trial. In this trial, 6006 patients with ST-elevation MI or non-ST elevation MI (NSTEMI) undergoing urgent PCI and receiving treatment with <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>, or <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> were randomly assigned to bivalirudin or heparin [<a href="#rid18">18</a>]. Most patients received radial artery access, and the use of GP IIb/IIIa inhibitors was not intended. The primary composite end point (death from any cause, MI, or major bleeding at 180 days) occurred in 12.3 percent in the bivalirudin group and 12.8 percent in the heparin group (hazard ratio 0.96, 95% CI 0.83-1.10). In addition, no significant difference in the rate of definite stent thrombosis was found. While not powered to assess the individual end points in the composite, the trial did not find any apparent difference between the two anticoagulants for the individual components, including major bleeding, which was 8.6 percent in each group. The observed event rates were lower than those predicted.</p><p>Before VALIDATE-SWEDEHEART, <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> had been compared with heparin in three large randomized trials performed before the routine use of <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or before the routine use of the radial artery for access. These trials presented below suggested similar outcomes with the two anticoagulants, with the exception that major bleeding was increased in the two trials that planned combination of heparin with GP IIb/IIIa inhibitor. Since we do not recommend routine use of a GP IIb/IIIa inhibitor, there is no advantage to bivalirudin in most patients. (See  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In the ACUITY trial, nearly 14,000 patients with moderate- to high-risk ACS undergoing PCI were randomly assigned to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> (alone or with a GP IIb/IIIa inhibitor) or UFH or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (both with a GP IIb/IIIa inhibitor) [<a href="#rid19">19,20</a>]. Prior to randomization, about 64 percent of patients were receiving either UFH or enoxaparin, while about 36 percent were receiving neither. Primary end points included a composite of ischemic complications (death, MI, or unplanned revascularization for ischemia at 30 days) and major bleeding. Bivalirudin alone was noninferior to UFH or enoxaparin for the rate of ischemic complications (7.8 versus 7.3 percent, relative risk 1.08, 95% CI 0.93-1.24), while the rate of major bleeding was significantly lower with bivalirudin monotherapy (3.0 versus 5.7 percent, relative risk 0.53, 95% CI 0.43-0.65).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the ISAR-REACT 4 trial, 1721 patients with NSTEMI were randomly assigned to heparin plus GP IIb/IIIa inhibitor or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> monotherapy immediately before PCI [<a href="#rid21">21</a>]. At 30 days, there was no significant difference in the rate of the primary composite end point (death, large recurrent MI, urgent target–vessel revascularization, or major bleeding) between heparin plus GP IIb/IIIa inhibitor and bivalirudin (10.9 versus 11.0 percent; relative risk 0.99, 95% CI 0.74-1.32). There was significantly more major bleeding with UFH plus GP IIb/IIIa inhibitor (4.6 versus 2.6 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2015 MATRIX trial randomly assigned 7213 patients with an ACS (NSTEACS in 44 percent) to receive either <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> or UFH [<a href="#rid22">22</a>]. In patients receiving bivalirudin, GP IIb/IIIa inhibitors could only be given to patients with periprocedural ischemic complications; in patients receiving heparin, GP IIb/IIIa inhibitor (at the discretion of treating physician) could be given before PCI. GP IIb/IIIa inhibitor was given in 4.6 percent of patients in the bivalirudin group and 25.9 percent of patients in the heparin group. At 30 days, comparing bivalirudin with heparin, there was no difference in the rates of the primary end points of major adverse cardiovascular events, a composite of death, MI, or stroke; or net adverse clinical events, a composite of major bleeding or major adverse cardiovascular event (10.3 versus 10.9 percent; relative risk 0.94, 95% CI 0.81-1.09 and 11.2 versus 12.4 percent; relative risk 0.89, 95% CI 0.78-1.03, respectively).</p><p></p><p class="bulletIndent1">The rate of definite stent thrombosis was borderline higher with <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> (1.0 versus 0.6 percent; rate ratio 1.71, 95% CI 1.00-2.93). However, there was no significant difference in the rate of definite or probable stent thrombosis.</p><p></p><p class="bulletIndent1">The rate of Bleeding Academic Research Consortium 3 or 5 bleeding  (<a class="graphic graphic_table graphicRef77838" href="/d/graphic/77838.html" rel="external">table 2</a>) was lower in the <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> group (1.4 versus 2.5 percent; rate ratio 0.55, 95% CI 0.39-0.78), but the relevance of this finding is unclear given the marked asymmetry in the use of GP IIb/IIIa inhibitors in the two treatment groups (4.6 percent with bivalirudin versus 25.9 percent with heparin).</p><p></p><p class="bulletIndent1">At one year, comparing <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> with heparin, there was no difference in the rates of the primary end points of major adverse cardiovascular events or net adverse clinical events (15.8 versus 16.8 percent; relative risk 0.94, 95% CI 0.83-1.05 and 17.0 versus 18.4 percent; relative risk 0.91, 95% CI 0.81-1.02, respectively) [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H2872643105"><span class="h2">Fondaparinux</span><span class="headingEndMark"> — </span>For most patients with NSTEACS managed with an invasive strategy, we prefer anticoagulation with UFH (see <a class="local">'Unfractionated heparin compared with bivalirudin'</a> above). We do not routinely use <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> due to the possibility of an increased rate of stent thrombosis and thus a requirement to use heparin at the same time. Fondaparinux may be a reasonable anticoagulant choice in ACS patients at increased risk of bleeding  (<a class="graphic graphic_table graphicRef50176" href="/d/graphic/50176.html" rel="external">table 1</a>), based principally on the results of the OASIS-5 trial discussed below.</p><p>However, some patients will have been started on <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> for reasons such as a concern for bleeding. For those individuals undergoing PCI in whom fondaparinux was chosen as the initial anticoagulant, we strongly recommend switching to standard-dose UFH (see <a class="local">'Anticoagulant Use'</a> below), with further dosing of the latter based on the activated clotting time, as was done in the FUTURA/OASIS 8 trial (discussed below). Although <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> has not been evaluated in patients started on fondaparinux, we believe that switching to bivalirudin is also a reasonable anticoagulant strategy.</p><p>In OASIS-5, 20,078 NSTEACS patients were randomly assigned to <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> (2.5 mg/day) or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (1 mg/kg twice daily) for a mean of six days (anticoagulant was generally stopped after PCI, if it was performed) [<a href="#rid24">24-27</a>]. Over 60 percent of patients underwent catheterization and over 30 percent had PCI. Patients received weight-adjusted UFH during PCI if the last dose of enoxaparin was greater than six hours before the procedure. For patients who received an initial dose of subcutaneous fondaparinux and then underwent PCI, an additional dose was given intravenously  (<a class="graphic graphic_table graphicRef57341" href="/d/graphic/57341.html" rel="external">table 3</a>). After isolated reports of catheter thrombosis, a protocol amendment allowed for the addition of open-label UFH in patients receiving fondaparinux at the discretion of the investigator.</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The two groups had similar rates of the primary end point, defined as death, MI, or refractory ischemia at nine days (5.8 versus 5.7 percent with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>), and the secondary end point of death or MI (4.1 percent in both groups).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At longer-term follow-up, there was a reduction in the primary end point with <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> at 30 days (2.9 versus 3.5 percent, hazard ratio 0.83, 95% CI 0.71-0.97) and six months (5.8 versus 6.5 percent, hazard ratio 0.89, 95% CI 0.81-1.00). These differences were entirely due to a significantly lower rate of death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rate of major bleeding was significantly reduced with <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> (2.2 versus 4.1 percent, hazard ratio 0.52, 95% CI 0.44-0.61). The benefits and risks were consistent among various subgroups, including age and sex, the spectrum of renal function, and whether or not revascularization was performed within nine days [<a href="#rid24">24,25</a>].</p><p></p><p>The safety of <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> relative to <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> was confirmed in two important prespecified subgroups: those who underwent PCI [<a href="#rid26">26</a>], and those in patients who received GP IIb/IIIa inhibitors [<a href="#rid27">27</a>].</p><p>However, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> was associated with a small but significant increase in the rate of catheter-related thrombi (in patients undergoing PCI) compared with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (0.9 versus 0.4 percent). The frequency of catheter-related thrombi was significantly reduced in both groups in those patients who received open-label UFH before the procedure.</p><p>The observation in the OASIS-5 trial of a small but significant increase in catheter-related thrombi, which was mitigated by the use of UFH, raises the question as to the optimal dose of UFH in such patients. This issue was directly addressed in the FUTURA/OASIS 8 trial in which 2026 high-risk patients with NSTEACS treated with <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> and scheduled to undergo PCI within 72 hours were randomly assigned to either a standard-dose UFH regimen (85 units/kg bolus with additional boluses based on an activated clotting time dosing algorithm) or a fixed low dose (50 units/kg without activated clotting time) [<a href="#rid28">28</a>]. For patients receiving a GP IIb/IIIa inhibitor, the UFH bolus in the standard-dose group was lowered to 50 units/kg.</p><p>At 48 hours after PCI, there was no significant difference between low-dose and standard regimens in the rate of the primary composite end point of major bleeding, minor bleeding, or major vascular access-site complications (4.7 versus 5.8 percent, respectively). The composite secondary outcome of major bleeding at 48 hours with death, MI, or target vessel revascularization within 30 days occurred more often in the low-dose group, nearly attaining statistical significance (5.8 versus 3.9 percent; odds ratio 1.51, 95% CI 1.00-2.28). Catheter thrombus rates were very low and not statistically different in the two groups (0.5 and 0.1 percent, respectively). (See  <a class="medical medical_review" href="/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H100954534"><span class="h1">ANTICOAGULANT USE</span><span class="headingEndMark"> — </span>The type and dose of anticoagulant depends on whether the patient will be undergoing a conservative or invasive approach and for the latter, whether it is started prior to arrival in the catheterization laboratory or in it. For all patients undergoing percutaneous coronary intervention (PCI), the use of an activated clotting time (ACT) goal is important in heparin management.</p><p class="headingAnchor" id="H1182398053"><span class="h2">Conservative approach</span><span class="headingEndMark"> — </span>We prefer <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> for these patients, using the following initial doses (see <a class="local">'Conservative approach'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> – 2.5 mg subcutaneously once daily in patients managed with a noninvasive strategy. (See <a class="local">'Fondaparinux'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">Enoxaparin</a> – No loading dose is necessary. Dosing is 1 mg/kg subcutaneously every 12 hours or for patients with an estimated creatinine clearance less than 30 mL/min, 1 mg/kg subcutaneously daily.</p><p></p><p class="headingAnchor" id="H2557113492"><span class="h2">Invasive approach</span><span class="headingEndMark"> — </span>For patients who are being considered for an invasive approach, we prefer <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) in most cases. (See <a class="local">'Invasive approach'</a> above.)</p><p>Anticoagulant dosing will depend on the whether the anticoagulant is started before arrival to the catheterization laboratory or in it. If it started before arrival to the catheterization laboratory (for example in an emergency department), we prefer UFH or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> using the following dosing:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH</strong> – We give an intravenous bolus of 60 units/kg (maximum dose 4000 to 5000 units) followed by 12 units/kg per hour intravenously (maximum dose 1000 units per hour) to achieve an activated partial thromboplastin time of 50 to 75 seconds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> – Intravenous bolus of 0.1 mg/kg and an infusion of 0.25 mg/kg per hour if started before angiography; if PCI is performed, an additional 0.5 mg/kg bolus is given, and the infusion rate is increased to 1.75 mg/kg per hour. If started in the catheterization laboratory at the time of PCI, intravenous bolus of 0.75 mg/kg and an infusion of 1.75 mg/kg per hour is appropriate.</p><p></p><p>For patients who ultimately undergo PCI, anticoagulant dosing depends on whether the patient arrives on anticoagulant and if so which one:</p><p class="bulletIndent1"><span class="glyph">●</span>If no anticoagulant was given prior to PCI, we give an initial intravenous UFH bolus of 70 to 100 units/kg to achieve an ACT of 250 to 300 seconds if glycoprotein (GP) IIb/IIIa inhibitor is not intended to be used or 50 to 70 units/kg to achieve an ACT of 200 to 250 seconds if GP IIb/IIIa inhibitor is intended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If UFH was administered, we give an additional bolus of UFH after sheath insertion if needed to target an ACT of 250 to 300 seconds if a GP IIb/IIIa inhibitor has not been given and is not planned during PCI. For such patients who will receive a GP IIb/IIIa inhibitor, we give additional UFH as needed to target an ACT of 200 to 250 seconds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> was initiated and two or more doses were given, and the last dose was given less than eight hours earlier, we proceed without additional enoxaparin. If a patient was given only one dose or the last dose was more than eight hours earlier, we give an additional intravenous bolus of enoxaparin (0.3 mg per kg). It may be better to continue with enoxaparin rather than switching to UFH, especially if anticoagulation may be continued after the procedure, since extrapolation from SYNERGY suggests that switching to UFH may be associated with an increased risk of death or MI at 30 days. (See <a class="local">'Unfractionated heparin compared with enoxaparin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> was initiated before arrival in the catheterization laboratory, we give UFH 85 units/kg bolus with additional boluses based on an ACT dosing algorithm. (See <a class="local">'Fondaparinux'</a> above.)</p><p></p><p class="headingAnchor" id="H167446356"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of anticoagulant therapy depends on the initial management strategy. Although the optimal treatment length has not been determined, the following represent commonly employed regimens in clinical practice (which we consider reasonable):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing PCI, anticoagulant therapy is stopped at the end of the procedure in uncomplicated cases. Continuation of anticoagulation beyond the times suggested above should be undertaken only if:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The PCI is complicated and there is an ongoing risk of recurrent ischemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is evidence of high risk for systemic or venous thromboembolism (anterior ST-elevation MI, severe left ventricular dysfunction, heart failure, history of systemic or pulmonary embolus, or echocardiographic evidence of mitral or left ventricular thrombus) or a preexistent rationale for long-term anticoagulation, such as patients with prosthetic heart valves or atrial fibrillation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In cases where <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> is used as the anticoagulation strategy and a platelet P2Y<sub>12</sub> receptor blocker has been given just before or after PCI, it is reasonable to continue a full-infusion dose of bivalirudin (1.75 mg/kg/hour) for four hours after the procedure [<a href="#rid20">20,29-32</a>]. (See  <a class="medical medical_review" href="/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Bivalirudin'</a> and <a class="local">'Unfractionated heparin compared with bivalirudin'</a> above and  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Anticoagulation after PCI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing a noninvasive (conservative) strategy who are receiving dual antiplatelet therapy, we suggest a minimum of 48 hours for the duration of anticoagulation.</p><p></p><p class="headingAnchor" id="H4041227502"><span class="h2">Heparin-induced thrombocytopenia</span><span class="headingEndMark"> — </span>The incidence of immune-mediated heparin-induced thrombocytopenia (HIT) is approximately 2.5 to 3.0 percent in patients exposed to UFH for more than four days [<a href="#rid33">33</a>]. The incidence is much lower in patients treated with UFH for less than four days (0.2 percent) and in those treated with LMWH (0.2 versus 2.6 percent with UFH in a meta-analysis of studies that mostly consisted of patients who had undergone orthopedic surgery) [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p>Based upon these observations, we suggest that the platelet count be measured serially in patients treated with UFH. In patients with a history of HIT, or in whom HIT develops or is suspected while on UFH therapy, the preferred anticoagulant is <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> if they are undergoing PCI. For HIT patients receiving a conservative approach, we prefer <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>. (See  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a> and <a class="local">'Our approach'</a> above.)</p><p class="headingAnchor" id="H100953299"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Guidelines for the use of anticoagulant therapy in patients with NSTEACS are available from the American College of Cardiology/American Heart Association (2014) [<a href="#rid34">34</a>], and the European Society of Cardiology/European Association for Cardio-Thoracic Surgery (2014) [<a href="#rid35">35</a>]. Each of the guidelines makes a strong recommendation for the use of anticoagulant therapy in all patients with ACS.</p><p>The following are important points made by in these guidelines:</p><p class="bulletIndent1"><span class="glyph">●</span>From the American College of Cardiology/American Heart Association:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients in whom an invasive strategy is selected, a recommendation is made for the use of <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH), or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients in whom a conservative strategy is selected, a recommendation is made for the use <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, or UFH, with the first two preferred to the latter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the 2015 European Society of Cardiology guideline for the management of ACS in patients without persistent ST-segment elevation, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> is recommended as having the most favorable efficacy-safety profile regardless of the management strategy. In patients undergoing percutaneous coronary intervention treated with fondaparinux, a single intravenous bolus of UFH is recommended during the procedure.</p><p></p><p class="headingAnchor" id="H3037764762"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a>.)</p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulant therapy</strong> – We recommend anticoagulant therapy for all patients with NSTEACS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). This recommendation is made for patients irrespective of whether an invasive or a conservative approach is taken. Anticoagulant therapy should be given as soon as possible after diagnosis and should be given in conjunction with recommended antiplatelet therapy. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type of therapy based on revascularization strategy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Early invasive strategy</strong> – For NSTEACS patients managed with an early invasive strategy (angiography and possible revascularization within 48 hours), we recommend UFH rather than <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>, <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, or <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Invasive approach'</a> above.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> is a reasonable alternative to heparin plus a glycoprotein IIb/IIIa inhibitor in patients who have undergone coronary angiography without an anticoagulant having been started. (See <a class="local">'Unfractionated heparin compared with bivalirudin'</a> above.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> has little role in patients undergoing an invasive approach due to reasons of cost (when compared with UFH) and the requirement for the coadministration of UFH prior to percutaneous coronary intervention.</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">Enoxaparin</a> has no role in patients undergoing an invasive approach due to a significant increase in the risk of bleeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Conservative or noninvasive strategy</strong> – For NSTEACS patients in whom a conservative (noninvasive) strategy is planned, we recommend either <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> in preference to either UFH or <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Our approach'</a> above and <a class="local">'Conservative approach'</a> above.)</p><p></p><p class="bulletIndent3">The choice between <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> and <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> should be guided by issues of cost and local practice. For patients at higher risk of bleeding  (<a class="graphic graphic_table graphicRef50176" href="/d/graphic/50176.html" rel="external">table 1</a>), we suggest fondaparinux (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="headingAnchor" id="H2109311545"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Simons, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20:1553.</a></li><li><a class="nounderline abstract_t">Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146:304.</a></li><li><a class="nounderline abstract_t">Katsouras C, Michalis LK, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005; 150:385.</a></li><li><a class="nounderline abstract_t">Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96:61.</a></li><li><a class="nounderline abstract_t">Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999; 354:701.</a></li><li><a class="nounderline abstract_t">Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.</a></li><li><a class="nounderline abstract_t">Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355:1936.</a></li><li><a class="nounderline abstract_t">Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347:561.</a></li><li><a class="nounderline abstract_t">Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447.</a></li><li><a class="nounderline abstract_t">Berkowitz SD, Stinnett S, Cohen M, et al. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001; 88:1230.</a></li><li><a class="nounderline abstract_t">Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000; 36:693.</a></li><li><a class="nounderline abstract_t">Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100:1593.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000; 36:1812.</a></li><li><a class="nounderline abstract_t">Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292:55.</a></li><li><a class="nounderline abstract_t">Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.</a></li><li><a class="nounderline abstract_t">Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005; 294:2594.</a></li><li><a class="nounderline abstract_t">Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017; 377:1132.</a></li><li><a class="nounderline abstract_t">Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203.</a></li><li><a class="nounderline abstract_t">Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369:907.</a></li><li><a class="nounderline abstract_t">Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365:1980.</a></li><li><a class="nounderline abstract_t">Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015; 373:997.</a></li><li><a class="nounderline abstract_t">Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 2018; 392:835.</a></li><li><a class="nounderline abstract_t">Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464.</a></li><li><a class="nounderline abstract_t">Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007; 147:304.</a></li><li><a class="nounderline abstract_t">Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50:1742.</a></li><li><a class="nounderline abstract_t">Jolly SS, Faxon DP, Fox KA, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 2009; 54:468.</a></li><li><a class="nounderline abstract_t">FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010; 304:1339.</a></li><li><a class="nounderline abstract_t">Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333:764.</a></li><li><a class="nounderline abstract_t">Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.</a></li><li><a class="nounderline abstract_t">Gargiulo G, Carrara G, Frigoli E, et al. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. J Am Coll Cardiol 2019; 73:758.</a></li><li><a class="nounderline abstract_t">Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.</a></li><li><a class="nounderline abstract_t">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2354.</a></li><li><a class="nounderline abstract_t">Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267.</a></li></ol></div><div id="topicVersionRevision">Topic 93 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529323" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891200" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169312" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236418" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475180" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087958" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Direct thrombin inhibitors in cardiovascular medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830196" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859038" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596317" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250846" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728348" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987586" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517729" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092649" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238590" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304073" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844201" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124018" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bivalirudin for patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368152" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077909" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26324049" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153988" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of fondaparinux and enoxaparin in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785485" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17964037" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628124" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805623" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7643883" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499566" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bivalirudin during primary PCI in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588269" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784669" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985543" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25249586" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320110" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
